The single-nucleotide polymorphisms (SNPs) rs402710 (5p15.33), rs16969968 and rs8034191 (15q25.1) have been consistently identified by genome-wide association studies (GWAS) as significant predictors of lung cancer risk, while rs4324798 (6p22.1) was previously found to influence survival time in small-cell lung cancer (SCLC) patients. Using the same population of one of the original GWAS, we investigated whether the selected SNPs and 31 others (also identified in GWAS) influence survival time, assuming an additive model. The effect of each polymorphism on all cause survival was estimated in 1094 lung cancer patients, and lung cancer-specific survival in 763 patients, using Cox regression adjusted for a priori confounders and competing causes of death where appropriate. Overall, after 1558 person-years of post-diagnostic follow-up, 874 deaths occurred from all causes, including 690 from lung cancer. In the lung cancer-specific survival analysis (1102 personyears), only rs7452888 (6q27) and rs2710994 (7p15.3) modified survival, with adjusted hazard ratios of 1.19 (P 5 0.009) and 1.32 (P 5 0.011) respectively, taking competing risks into account. Some weak associations were identified in subgroup analysis for rs16969968 and rs8034191 (15q25.1) and rs4324798 (6p22.1) and survival in never-smokers, as well as for rs402710 in current smokers and SCLC patients. In conclusion, rs402710 (5p15.33), rs16969968 and rs8034191 (both 15q25.1) and rs4324798 (6p22.1) were found to be unrelated to survival times in this large cohort of lung cancer patients, regardless of whether the cause of death was from lung cancer or not. However, rs7452888 (6q27) was identified as a possible candidate SNP to influence lung cancer survival, while
Introduction
Despite therapeutic advances, the 5-year relative survival rate for lung cancer, one of the most lethal cancer types, remains at 10% worldwide (1, 2) . So far, the majority of research efforts in associating genetic markers and lung cancer risk have been focused on incidence. Several genome-wide association studies (GWAS) have been conducted which identified strongly significant associations with single-nucleotide polymorphisms (SNPs) from a region on the long arm of chromosome 15: rs16969968, rs8034191 (15q25.1) (3-6) and on chromosome 5: rs402710 (5p15.33) (7) . Further studies provided validation in a Japanese population (8) and some evidence for biological plausibility: the region 15q25.1 (rs16969968 and rs8034191), located in the nicotinic cholinergic receptor subunit cluster, has been consistently associated with various aspects of smoking behaviour including nicotine addiction initiation, long-term dependence and the transition from light to heavy smoker, in European and Japanese populations (8) (9) (10) (11) (12) (13) ; rs402710 was also correlated with high tumour DNA adduct levels in a group of non-small-cell lung cancer (NSCLC) patients (14) .
Extending such associations to lung cancer survival can provide insight into the mechanistic pathways and contribute to knowledge on the determinants of lung cancer survival. A recent validation study by Yang et al. (15) found that of the top five lung cancer candidate SNPs (including the three described above), only rs4324798 (6p22.1) significantly altered overall survival time in small-cell lung cancer (SCLC) patients in a sample of 1700 lung cancer cases. Other genetic polymorphisms have been previously implicated in lung cancer survival, including the genes p53 (16), excision repair crosscomplementation group 1 (ERCC1) and x-ray repair crosscomplementing group 1 (XRCC1) (17, 18) . It is also conceivable that particular genotypes may be associated with characteristics of tumors that can accelerate or delay diagnosis which will, in turn, influence subsequent survival time.
In this study, we examined a selection of 35 candidate SNPs from a previous lung cancer risk GWAS and their effects on survival from all-causes and lung cancer specifically, among .1000 lung cancer cases in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
Patients and methods

Study population
The original GWAS and its replication in the current population have been published; details of recruitment, study design and data collection can be found in the supplementary information section in Hung et al. (4) and elsewhere (19) . Briefly, the EPIC study is a multicenter prospective cohort consisting of 23 centres in 10 European countries [France, Italy (Florence, Varese, Ragusa, Turin and Naples), Spain (Asturias, Granada, Murcia, Navarra and San Sebastian), UK (Cambridge, Oxford), The Netherlands (Utrecht and Bilthoven), Greece, Germany (Potsdam and Heidelberg), Sweden (Malmö and Umea), Denmark (Copenhagen and Aarhus) and Norway]. EPIC commenced at the beginning of the 1990s accruing prospectively .520 000 participants, aged mostly between 40 and 65 years at recruitment. The participants were recruited predominantly from the general population from a given geographic area (country, region or city). Exceptions are as follows: the French cohort consists of female members of a national health insurance program for school and university employees; the Spanish and Italian centres include sizable proportions of blood donors; the Utrecht and Florence cohorts are based on participants in a mammography screening program; the cohort in Oxford is deemed as 'health conscious' and includes vegetarians and healthy-eaters. Female-only cohorts are those from France, Norway, Utrecht and Naples. Detailed information on diet, lifestyle and socio-economic variables were obtained by questionnaire; anthropometric measurements and blood samples were also taken at recruitment.
The EPIC study was approved by the Ethical Review Board of the International Agency for Research on Cancer (IARC, Lyon, France). Informed written or oral (Oxford) consent, which covers the use of blood and associated data, was obtained from all participants who have provided samples.
Cancer incidence and mortality Identification of cancer cases was based either on population cancer registries (Denmark, Italy, The Netherlands, Norway, Spain, Sweden and the UK) or used a combination of methods including health insurance records, cancer and pathology registries and active follow-up through study subjects and their next of kin (France, Germany and Greece). Follow-up information was last updated in 2006. Coding of cases was based on the second revision of the International Classification of Diseases for Oncology (ICD-O-2). Deaths from lung cancer were identified using the equivalent of ICD-10 code C34 as the originating cause. The classification of cancer histology was based on the 1999 World Health Organization/International Association for the Study of Lung Cancer Histological Classification of Lung and Pleural Tumours (20) .
Selection of SNPs
We selected three SNPs that were consistently identified in previous GWAS on lung cancer: rs16969968 and rs8034191 and rs402710 (3) (4) (5) (6) (7) . In addition, we also selected rs4324798 which has been shown to affect survival in SCLC patients previously (15) . Furthermore, we included 31 SNPs, without a priori hypotheses, which were candidate lung cancer SNPs from the previous GWAS and its replication phase, based on their significance levels as well as their locations in or close to known genes (5, 8) . The complete list of SNPs investigated here is presented in Table I 
Statistical analysis
A total of 1244 patients were newly diagnosed with lung cancer between December 30, 1993 and December 19, 2005 in the cohort. Follow-up time was censored at the point at which .80% of all deaths had known causes and resulted in the removal of participants who had died from unknown causes of death in Denmark after December 31, 2004 and in Sweden after May 31, 2003 (n 5 42). Additionally, patients censored for reasons other than death (e.g. emigration, loss to follow-up), those cases that were ascertained post-mortem and those with missing information on educational attainment, lung cancer histology and unknown smoking status were excluded (n 5 107). The only French participant was also excluded from the analysis after the decision to adjust the Cox model by country of recruitment (n 5 1). This forms the overall population (n 5 1094) for all-cause mortality analysis (Population A).
In order to reduce possible errors due to the differential practices in coding of causes of death between the three Scandinavian countries and the rest of the EPIC, for lung cancer-specific mortality analysis, participants from Denmark (n 5 275), Sweden (n 5 44) and Norway (n 5 12) were excluded. This forms the overall Population B for lung cancerspecific mortality analysis. The flowchart of exclusions for both populations is shown in Figure 1 .
Furthermore, participants with missing or unsuccessful genotyping information were excluded from further regression analyses for each polymorphism in each population (A and B) (for details, see supplementary Table A, available at Mutagenesis Online).
Proportionality of hazards over time for each SNP was assessed using Kaplan-Meier plots. The effect of having nonreference alleles compared with reference alleles on the extent of patient post-diagnosis survival was estimated using univariate and multivariate Cox regression modeling assuming an additive model, adjusting for competing risks where appropriate. Further analyses were carried out for rs402710, rs16969968, rs8034191, rs4324798, rs7452888 and rs2710994, stratified by lung cancer histology, smoking status and geographic region (mutually adjusted using all covariates). The definitions of reference and non-reference alleles for each SNP are presented in Table I, and supplementary Table A, available at Mutagenesis Online, shows their frequency distributions. Results are expressed as hazard ratios (HRs) with 95% confidence intervals (95% CIs), along with the associated P-values. For rs402710, rs16969968, rs8034191and rs4324798, threshold for P-value was set at 0.05 since there are a priori hypotheses; for all other SNPs, multiple testing was taken into account with the threshold reduced to 0.016. Survival time was calculated as time between the date of diagnosis and the date of censoring event, defined as the last known date of vital status if the patient is alive or date of death from all causes or lung cancer specifically.
Survival analysis was performed using Stata version 11 (StataCorp., Lakeway Drive College Station, TX, USA). Power calculations were made using Power and Sample Size Calculations (PS) software version 3.0.
(21).
Results
In the analysis for all-cause mortality (i.e. using Population A), 1094 patients from nine countries were available. At the end of the last mortality update (November 2006), a total of 1558 years of post-diagnostic follow-up was accrued and 874 deaths occurred: 690 from lung cancer and 184 from other causes, with cancer (n 5 31, 31%), circulatory diseases (n 5 27, 15%) and respiratory diseases (n 5 25, 14%) as the three most prevalent groups. The total number was reduced to 763 patients and 595 deaths in Population B, of which 537 (90%) were from lung cancer. The median follow-up time from diagnosis to end event was 270 days in the entire cohort. The overall median survival time -defined as the point in time at which 50% of participants were alive-(95%CI) was 282 (258-309) days for survival from all causes in Population A and 315 (288-344) days for survival from lung cancer in Population B. The apparent longevity of the patients dying from lung cancer compared to all causes is an artifact due to the shallower curvatures of the cause-dependent survival functions since competing causes were not accounted for. In further analyses, the effects of competing causes of death were adjusted for in Cox regression analysis using a method based on proportional sub-hazards described by Fine and Grey to obtain sub-hazard ratios (SHRs) (22) .
Since all participants were lung cancer cases, ,10% were never-smokers, with the rest consisting of 30% former and 60% current smokers at time of entry into this prospective 
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Fig 1. Flowchart of exclusions for Populations A and B.
Single-nucleotide polymorphisms and lung cancer survival study, the details of population characteristics are presented in Table II .
rs402710 (5p15.33), rs16969968 and rs8034191 (both 15q25.1), rs4324798 (6p22.1) and survival Since rs16969968 and rs8034191 are in linkage disequilibrium (r 2 5 0.88), we will consider them jointly and any significant results will be attributed to the chromosomal region 15q25.1 rather to individual SNPs.
Univariate analysis did not identify statistically significant associations between these four gene variants and either survival endpoint. The results did not change after adjustments for a priori confounders sex, age at diagnosis (continuous), country of recruitment (to account for some of the differences across countries), highest level education attainment (primary or less, secondary and higher), lung cancer histology (unknown/unspecified, other including large cell carcinoma and sarcoma, adenocarcinoma, squamous cell carcinoma and SCLC) and smoking status (never, former and current).
All-cause mortality was also investigated in addition to lung cancer-specific mortality since it is likely that the deaths in the majority of the patients in this group can be directly or indirectly attributed to lung cancer. Competing causes of death were taken into account for lung cancer-specific mortality using both crude and adjusted models, but this did not change neither the size of the HRs nor their significance levels. The results of all models are presented in Table III .
Other SNPs and lung cancer-specific survival We have included 31 additional candidate SNPs from the previous GWAS and its replication phase, without a priori underlying biological hypotheses (5, 8) . rs7452888 (6q27) and rs2710994 (7q15.3) were the only polymorphisms which significantly influenced survival times with any consistency in this study, although only the P-values from crude analysis for rs2710994 (7q15.3) exceeded significance levels after Bonferroni correction for multiple testing (see Table III ).
Stratified analysis by smoking status rs402710 (5p15.33), rs16969968 and rs8034191 (both 15q25.1), rs4324798 (6p22.1), rs7452888 (6q27) and rs2710994 (7p15.3) were chosen to be investigated further in Population B by stratifying by lung cancer histology, smoking status and geographic region, using the fully adjusted model.
The results show that in never-smokers, the two 15q25.1 SNPs (rs16969968 and rs8034191) were found to be detrimental for all-cause mortality, with HRs and P-values (P) of 2.24 (P 5 0.002) and 2.68 (P , 0.000), respectively. A similar pattern was observed for lung cancer-specific mortality after adjustment for competing causes, albeit with attenuated HRs and P-values: 1.64 (P 5 0.041) and 1.69 (P 5 0.07, nonsignificant) respectively. The HRs for rs4324798 (6p22.1) for all-cause mortality was 3.11 (P 5 0.022), which was increased to 4.06 (P 5 0.004) for lung cancer-specific mortality (after adjustment for competing causes) in never-smokers. rs402710 (5p15.33) was also associated with a moderate increased risk of dying from lung cancer specifically in current smokers, with an HR of 1.18 (P 5 0.044), in current smokers.
The two SNPs without a priori hypothesis, rs7452888 (6q27) and rs2710994 (7p15.3), showed weak detrimental effects for lung cancer-specific mortality; their HRs after adjusting for competing events were 1.38 (P 5 0.025) in former smokers and 1.25 (P 5 0.013) in current smokers, respectively. Note that neither P-values exceeded the threshold after Bonferroni correction for multiple testing.
Stratified analysis by lung cancer histology
In patients with unspecified histology, the estimated HR for rs402710 (5p15.33) was 1.31 (P 5 0.035) for deaths from all causes; while rs4324798 was linked with an increased risk of lung cancer death but only after competing event adjustment (HRs: 2.02, P 5 0.042). The association between rs402710 (5p15.33) and lung cancer mortality remained stable after adjusting for competing risks in SCLC patients (HRs: 1.57, P 5 0.015 and 1.53, P 5 0.012, respectively). While rs7452888 (6q27) and rs2710994 (7p15.3) were both associated with higher risk of lung cancer mortality in adenocarcinomas, none remained significant after Bonferroni correction.
Stratified analysis by European region
We explored potential population stratification by splitting the study population into three geographic areas (small numbers in some countries made it impossible to stratify by country). These were North (Denmark, Sweden and Norway), middle (Germany, Netherlands and UK) and South Europe (Italy, Spain and Greece), which also capture some of the unmeasured influences (e.g. cultural, economic, etc.) that could affect the associations between gene variants and survival time. Weak effects were found for rs7452888 (6q27) and rs2710994 (7p15.3) in certain regions. However, no association was below the P-value threshold for multiple testing.
All results for both overall and stratified analysis can be found in Table IV Tables III and IV, in non-stratified analysis of all-cause mortality (Population A) and without competing events. This widens to up to 30% for lung cancer-specific mortality in Population B.
Discussion
In this large multi-centre cohort study from Europe, the polymorphisms rs402710 at chromosome 5p15.33, rs16969968 Table III . HRs from crude and multivariate Cox regression for all-cause mortality and lung cancer mortality (without and with competing causes), using Populations A and B, respectively, for the SNPs rs402710, rs16969968, rs8034191 rs4324798, rs7452888 and rs2710994
Model
All-cause mortality (Population A) Single-nucleotide polymorphisms and lung cancer survival Table IV . Stratified analysis results obtained from fully adjusted Cox regression for all-cause-mortality and lung cancer mortality (without and with competing causes), using Populations A and B, respectively, for the SNPs rs402710, rs16969968, rs8034191 rs4324798 , rs7452888 and rs2710994 SNP All-cause mortality (Population A) Lung cancer-specific mortality (Population B) (Table III) . Of all SNPs investigated here, rs4324798 (6p22.1) is the only one to have been found to affect survival in a previous study, but the effect was protective (HRs 5 0.46, P 5 0.001) and was significant only in SCLC patients after extensive adjustment for clinical and other factors including stage, treatment modality, tumour progression and smoking (15) . This is not confirmed by the current study as the HRs for rs4324798 in SCLC cases were all .1 and non-significant (see Table IV ). This could arise, at least in part, from the incomplete adjustment for clinical factors in the current study.
The results from stratified analysis were more compelling in never-smokers, where the chromosomal region 15q25.1 (rs16969968 and rs8034191), as well as rs4324798 (6p22.1) all altered survival from all causes and lung cancer. These findings could be due to small numbers of never-smokers (n 5 85 see Table IV and supplementary Table B , available at Mutagenesis Online), given the further stratification by lung cancer histology in the model, which produced unstable estimates. This is an unfortunate characteristic of lung cancer case-control studies which are usually comprised overwhelmingly of former-and current smokers. Care must be taken in the interpretation of the results. If the results are indicative of true associations, it may be reasonable to infer that the associations previously found between the variants investigated here and lung cancer incidence act through distinct biological pathways in survival. For instance, rs16966968 has been postulated to act through smoking addiction in its carcinogenicity; our observations in a modest group of never-smokers suggest that tobacco is not a predominant factor in the putative mechanism through which rs16969968 influences lung cancer survival.
Interestingly, rs402710's associations with lung cancerspecific deaths were found in current smokers and in SCLC patients, giving 18% and 53% increased risks, respectively, after competing causes adjustment. It has been suggested that rs402710 could be acting through the human telomerase reverse transcriptase (TERT) gene and regulating telomerase activity, which in turn has been previously implicated in lung cancer survival as well as carcinogenesis (7, 23) . Once again, appropriate caution needs to be exerted in the interpretation of such results from subgroups of patients.
In this study, the main focus has been placed on the 5p (rs402710), 15q (rs16969968 and rs8034191) and 6p (rs4324798) polymorphisms since the other individual SNPs investigated have few or no prior published studies. To our knowledge, this is the first time that the variants rs7452888 and rs2710994 have been linked to biological outcomes. rs7452888 is located in the gene XXyac-YX65C7_A.3, thought to be a processed pseudogene with no known protein product. Although its mechanism of action remains unidentified, its chromosomal region (6q27) has been linked to NSCLC in a Chinese population via gene scan (24) and to lung function (25) , while the implications of 6q27 in ovarian cancer led to the identification of a putative tumour suppressor gene, RPS6KA2 (26) . rs2710994 is located in the intronic region within the oxysterol binding protein-like 3 (OSBPL3), a family of intracellular lipid receptors proteins that participate in cholesterol metabolism. However, it appears that rs2710994 does not give rise to variations at the transcript level. The 7p.15.3 region where it is located has been previously implicated chiefly in lung adenomas in never-smokers via epidermal growth factor receptor (EGFR) amplification (27, 28) , although the results from this study show only a weak (non-significant after correction for multiple testing) association in this histological type and none in never-smokers.
Since studies that attempt to associate the 5p, 15q and chromosome 6 polymorphisms with lung cancer survival are currently limited, any result will require verification by other independent studies of similar or greater size; this is especially the case for the associations identified in never-smokers. The strength of our study is its population-based prospective design, which contributes to reduce potential bias. The overall median survival times for all-cause mortality (9.2 months) is consistent with literature values (29, 30) .
There are also limitations. Information on smoking behaviour was obtained at the point of recruitment rather than at diagnosis (average lapse time of 4.8 years), making it difficult to rule out the possibility of changes in smoking habits, that may be influenced by a number of non-genetic determinants, including the lung cancer diagnosis itself (31, 32) . Despite our effort to minimise possible bias by truncating follow-up to achieve 80% known cause of death in Denmark and Sweden, the proportion of deaths recorded as due to lung cancer in Denmark is 52%, considerably lower than the cohort average of 79%, possibly due to differences in coding practices. As a result, we excluded participants from the above countries as well as Norway due to the small number of deaths for lung cancer-specific analysis. The full models were adjusted by country of recruitment as a potential confounder, so that the differences across countries in the population were taken into account to some degree, including the geographic differences observed in allele frequency (see supplementary Table A , available at Mutagenesis Online). It is still possible that the results are subject to the effects of population stratification; therefore, a stratified analysis by region was conducted for North, middle and South Europe. Weak associations were identified only for rs2710994 in North and middle regions (Germany, Netherlands and UK). Some researchers have proposed that the within-country variations in genetic structure in Europe are modest so that if a case-control study is well designed (i.e. no systematic selection bias of cases and controls), the influence of population stratification would likely to be moderate after controlling for the geographic origins of the samples (33) (34) (35) (36) . Using the weak associations obtained for rs2710994 in this study as benchmarks, the HRs showed limited extent of variation by region: the North seems to differ from the other two regions in all-causes survival which could be due to the apparent heterogeneity in rs2710994's allele frequency distribution.
Clinical factors that influence survival such as cancer staging at diagnosis and the type of treatment received (chemotherapy and surgery) were unavailable at the time of analysis. Lung cancer histology, the only surrogate clinical information available, was incorporated into the fully adjusted model as one of the a priori co-variates; further analysis was also performed stratifing by histology categories. Staging in lung cancer is the most influential factor to predict survival time; the 5-year prognosis can vary greatly between Stages I and IV, not having this information is therefore a limitation of the current study. However, we argue that these results are still meaningful in their own right. In fact, it is likely that some of the genetic variants mediate their effect on survival through established clinical risk factors, for instance stage at diagnosis, and in turn, treatment modality and response. Hence, such factors could act as intermediate variables or effect modifiers rather than confounders for the relationships under investigation. Considering the fact that survival time for patients diagnosed with lung cancer is very short (median survival was 9 month in current study), identifying potential predictive biomarkers may bring real clinical advantages. Of course, such findings will certainly benefit from further and more comprehensive examination by other studies with clinical data, which will elucidate the biological mechanisms of any associations found by the current study.
In conclusion, this study has identified rs7452888 (6q27) and rs2710994 (7p15.3) as possible candidate genetic variants that can alter post-diagnostic survival in lung cancer patients. Results also suggest that it is possible for the other SNPs at chromosomal regions 15q25.1 (rs8034191 and rs16969968) and 6p22.1 (rs4324798) to be relevant to survival in lung cancer patients who were never-smokers, and rs402710 (5p15.33) for current smokers and the SCLC histological subtype, although small numbers in some strata (i.e. neversmokers) suggest caution in the interpretation of stratified findings.
Supplementary data
Supplementary Tables 1-4 are available at Mutagenesis Online.
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